The Oncology Institute, Inc. TOI Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Other Operating Income by Business | ||||||
| Clinical trials & other | $3.28M-22.7% | $4.24M-22.4% | $5.46M-16.6% | $6.54M-2.2% | $6.69M-4.5% | |
| Patient services | $17.43M-1.5% | $17.7M+23.9% | $14.28M+6.0% | $13.47M-9.8% | $14.94M+23.0% | |
| Total segment amortization by Business | ||||||
| Clinical trials & other | $55K-50.0% | $110K-50.0% | $220K-20.0% | $275K0.0% | $275K0.0% | |
| Patient services | $2.87M0.0% | $2.87M-20.1% | $3.59M0.0% | $3.59M0.0% | $3.59M0.0% | |
| Total Assets by Business | ||||||
| Clinical trials & other | $20.27M-8.8% | $22.24M-10.2% | $24.78M-15.0% | $29.16M-15.2% | $34.4M-5.2% | |
| Patient services | $301.89M+6.1% | $284.53M+2.2% | $278.32M+0.5% | $276.8M-0.2% | $277.49M-4.2% | |
| Depreciation expense by Business | ||||||
| Clinical trials & other | $8K-20.0% | $10K+150% | $4K0.0% | $4K-88.2% | $34K+6.3% | |
| Patient services | $2.9M-0.6% | $2.92M-1.1% | $2.95M+6.4% | $2.77M+10.7% | $2.51M+10.6% | |
| Total operating revenue by Product | ||||||
| Capitated revenue | $89.92M+11.7% | $80.48M+8.2% | $74.42M+8.4% | $68.66M+0.2% | $68.51M-0.3% | |
| Clinical trials & other | $3.33M-27.0% | $4.56M-27.8% | $6.32M-18.8% | $7.79M-4.2% | $8.12M-5.7% | |
| FFS revenue | $145.09M-2.3% | $148.51M+2.5% | $144.96M+3.3% | $140.27M+2.4% | $136.98M+0.6% | |
| Patient services | $235.01M+2.6% | $228.99M+4.4% | $219.37M+5.0% | $208.93M+1.7% | $205.5M+0.3% | |
| Total Assets by Product | ||||||
| Capitated accounts receivable | $9.95M-18.9% | $12.26M-3.8% | $12.75M— | —— | —— | |
| FFS accounts receivable | $136.25M+3.8% | $131.2M+7.2% | $122.36M— | —— | —— | |
| IV drug inventory | $36.52M+23.8% | $29.5M+5.4% | $27.97M— | —— | —— | |
| Oral drug accounts receivable | $37.56M+6.7% | $35.18M+3.2% | $34.1M— | —— | —— | |
| Oral drug inventory | $39.31M+14.4% | $34.36M+18.3% | $29.04M— | —— | —— | |
| Other assets | $140.28M+9.9% | $127.6M-5.8% | $135.43M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
